Evidence map›Paper›PMID 28283782›Full record

ArticleJournal of cancer research and clinical oncology2017

Prostate transitional zone volume-based nomogram for predicting prostate cancer and high progression prostate cancer in a real-world population.

Yanqing Wang, Shaowei Xie, Xun Shangguan, Jiahua Pan, Yinjie Zhu, Zhixiang Xin, Fan Xu, Xiaoguang Shao, Liancheng Fan, Jianjun Sha and 3 more

Abstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Prostate zones and cancer: lost in transition?Nature reviews. Urology · 2022
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yanqing WangDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Pudong District, Shanghai, 200127, People's Republic of China.
Shaowei XieDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Pudong District, Shanghai, 200127, People's Republic of China.
Xun ShangguanDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Pudong District, Shanghai, 200127, People's Republic of China.
Jiahua PanDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Pudong District, Shanghai, 200127, People's Republic of China.
Yinjie ZhuDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Pudong District, Shanghai, 200127, People's Republic of China.
Zhixiang XinDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Pudong District, Shanghai, 200127, People's Republic of China.
Fan XuDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Pudong District, Shanghai, 200127, People's Republic of China.
Xiaoguang ShaoDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Pudong District, Shanghai, 200127, People's Republic of China.
Liancheng FanDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Pudong District, Shanghai, 200127, People's Republic of China.
Jianjun ShaDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Pudong District, Shanghai, 200127, People's Republic of China.
Qiang LiuDepartment of Pathology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Baijun DongDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Pudong District, Shanghai, 200127, People's Republic of China. dongbaijun@renji.com.
Wei XueDepartment of Urology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, 160 Pujian Road, Pudong District, Shanghai, 200127, People's Republic of China. xuewei@renji.com.

Funding

EPA EP-C-16-015
6 · The paper itself

Abstract

purposeTo evaluate and compare the efficacy of prostate volume (PV), transitional zone volume (TZV), and prostate volume index (PVI, the ratio of TZV to peripheral zone volume) in the identification of men at risk of prostate cancer (PCa) and high-progression PCa (HPPCa) at the initial biopsy (IBX) in a real-world population.

methodsFrom Jul 2014 to Aug 2016, data on 1144 patients who had undergone the initial prostate biopsies were prospectively collected and analyzed. Univariate and multivariate logistic regression analyses were performed to identify the independent predictors for PCa and HPPCa. Based on independent predictors, nomogram models were developed and internally validated to assess a man's risk of harboring PCa and HPPCa.

resultsThe detection rates of PCa and HPPCa were 43.09% (493/1144) and 39.16% (448/1144), respectively. In the multivariate analyses, age, PSA, TZV, DRE, and TRUS instead of PV or PVI were independent predictors for PCa and HPPCa, percent free PSA was independent predictor for PCa not for HPPCa. Such independent predictors were finally included in the nomogram models. The AUCs of TZV-based nomogram models were 87.0% for PCa and 87.7% for HPPCa, which were higher than that of PSA alone or other predictive models.

conclusionsTZV is a better predictive biomarker than PV or PVI for PCa and HPPCa, we recommend adding TZV but not PV or PVI to the nomogram models to improve the predictive accuracy of PCa and HPPCa at IBX.

Indexed as

NomogramsAgedArea Under CurveDisease ProgressionHumansMaleMiddle AgedProstatic NeoplasmsRisk FactorsROC CurveSensitivity and SpecificityBiopsyNomogramProstatic neoplasmTransitional zone volume

Identifiers

PMID28283782
PMCPMC11819286

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.